

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

C32 [Human melanoma]

RRID:CVCL_1097

Type: Cell Line

Proper Citation

RRID:CVCL_1097

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1097

Proper Citation: RRID:CVCL_1097

Description: Cell line C32 [Human melanoma] is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: [PMID:3182330](#), [PMID:3900210](#), [PMID:9354451](#), [PMID:12068308](#), [PMID:15048078](#), [PMID:15467732](#), [PMID:17363583](#), [PMID:17516929](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22383533](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: MET genetic alteration cell panel (ATCC TCP-1036)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: C32 [Human melanoma]

Synonyms: C-32, C32-mel, C32 mel, C32r

Cross References: CLO:CLO_0002113, EFO:EFO_0006364, CLDB:cl566, CLDB:cl5173, AddexBio:C0020002/443, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1585, BCRC:60081, BioGRID_ORCS_Cell_line:581, BioSample:SAMN03472821,

BioSample:SAMN10988316, cancercellines:CVCL_1097, Cell_Model_Passport:SIDM00890, CGH-DB:9321-4, ChEMBL-Cells:ChEMBL3308713, ChEMBL-Targets:ChEMBL1075401, Cosmic:687432, Cosmic:888988, Cosmic:905234, Cosmic:906830, Cosmic:928725, Cosmic:933006, Cosmic:1022272, Cosmic:1155267, Cosmic:1458960, Cosmic:1995352, Cosmic-CLP:906830, DepMap:ACH-000580, ECACC:87090201, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906830, GEO:GSM162931, GEO:GSM206449, GEO:GSM215721, GEO:GSM827471, GEO:GSM886898, GEO:GSM887963, GEO:GSM1138788, GEO:GSM1669636, IARC_TP53:21204, IZSLER:BS TCL 150, LiGeA:CCLE_275, LINCS_HMS:50112, LINCS_LDP:LCL-1238, PharmacDB:C32_154_2019, PRIDE:PXD030304, Progenetix:CVCL_1097, PubChem_Cell_line:CVCL_1097, Wikidata:Q27902869

ID: CVCL_1097

Record Creation Time: 20220427T215434+0000

Record Last Update: 20260905T174501+0000

Ratings and Alerts

No rating or validation information has been found for C32 [Human melanoma].

No alerts have been found for C32 [Human melanoma].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Poelchen J, et al. (2025) Generation and functional analysis of melanoma antigen-specific CD8+ T cells derived from S/MAR vector-transfected human induced pluripotent stem cells. International journal of cancer, 157(9), 1876.

Guerrero Zuniga A, et al. (2024) Sustained ERK signaling promotes G2 cell cycle exit and primes cells for whole-genome duplication. Developmental cell, 59(13), 1724.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. Cell reports, 43(8), 114622.

Xi H, et al. (2023) Repurposing fluphenazine to suppress melanoma brain, lung and bone metastasis by inducing G0/G1 cell cycle arrest and apoptosis and disrupting autophagic flux. *Clinical & experimental metastasis*, 40(2), 161.

Tagore M, et al. (2023) GABA Regulates Electrical Activity and Tumor Initiation in Melanoma. *Cancer discovery*, 13(10), 2270.

Melacarne A, et al. (2021) Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. *Cell reports*, 36(1), 109312.

Sun Q, et al. (2021) FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. *International journal of cancer*, 149(3), 657.

Wnorowski A, et al. (2020) Toxicity of Carlina Oxide-A Natural Polyacetylene from the Carlina acaulis Roots-In Vitro and In Vivo Study. *Toxins*, 12(4).

Gerosa L, et al. (2020) Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells. *Cell systems*, 11(5), 478.

Xu J, et al. (2018) GPR68 Senses Flow and Is Essential for Vascular Physiology. *Cell*, 173(3), 762.

Strzemski M, et al. (2017) In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka. *Frontiers in pharmacology*, 8, 371.